Stem Cell Treatment — Procedure Guide, Recovery & Risks | MyMedicPlus

Stem cell treatment uses the regenerative, immunomodulatory, or cell-replacement properties of stem cells (hematopoietic, mesenchymal, or induced pluripotent) to treat disease. Cells may be autologous (from the patient) or allogeneic (donor-derived) and are delivered intravenously, intrathecally, intra-articularly, or by direct tissue injection.

Approved indications include hematopoietic disorders (sickle cell disease, thalassemia, aplastic anemia), limbal stem cell deficiency (corneal repair), and cartilage repair (autologous chondrocyte implantation). Investigational uses include multiple sclerosis, Parkinson's disease, spinal cord injury, and diabetes under controlled clinical trials.

Cells are sourced from bone marrow aspiration, adipose tissue liposuction, cord blood, or peripheral apheresis and processed under GMP (Good Manufacturing Practice) conditions. Quality-control testing confirms viability and sterility. Cells are then administered by the appropriate route under monitoring; intravenous infusions take 1-4 hours with vital sign observation.

Most infusion-based treatments are outpatient. Flu-like reactions (fever, myalgia) may occur in the first 24-48 hours and are managed with paracetamol and hydration. Patients are observed for 2-4 hours post-infusion. Clinical benefit (where proven) emerges over weeks to months; follow-up imaging and biomarkers monitor response.

Infusion reactions (fever, rigors, hypotension) occur in 2-5% of patients. Allogeneic therapy carries rejection and GVHD risk. Pluripotent stem cells (iPSC) carry theoretical tumorigenesis risk. Many advertised stem cell treatments lack regulatory approval and published safety data; unproven therapies carry risks of harm from inadequately controlled cell products.

Hematopoietic SCT cures 70-90% of thalassemia major cases with matched sibling donors. Limbal stem cell transplant restores vision in 60-80% of patients with corneal stem cell deficiency. Autologous chondrocyte implantation achieves cartilage repair in 60-70% of knee defects at 2 years. Robust evidence for other indications remains emerging.